

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services 7500
Security Boulevard, Mail Stop C1-22-06
Baltimore, Maryland 21244-1850



MEDICARE PARTS C AND D OVERSIGHT AND ENFORCEMENT GROUP

December 31, 2025

Mr. Dominic Henriques
Chief Executive Officer
Gold Kidney of Florida, Inc.
4600 E Washington St, #300
Phoenix, AZ 85034

Re: Notice of Release of Intermediate Sanction (Suspension of Enrollment) for Medicare Advantage-Prescription Drug Plan Contract Number: H1526

Dear Mr. Henriques:

On September 29, 2025, the Centers for Medicare & Medicaid Services (CMS) imposed an intermediate sanction on Gold Kidney of Florida Inc. ("Gold Kidney") contract H1526, thereby suspending enrollment for its Medicare Advantage-Prescription Drug Plan (MA-PD) contract. The sanction was imposed because the Florida Office of Insurance Regulation (FL OIR) and Gold Kidney entered a consent order which stated that Gold Kidney's "authority to enroll new subscribers for plan year 2025 shall be suspended through December 15, 2025". Florida took this action after determining that Gold Kidney failed to obtain required prior approvals for key executive appointments, significantly delayed mandatory filings, failed to provide required financial documentation and planning materials, and demonstrated substantial variances between projected and actual financial performance.

Because Gold Kidney was not permitted to accept new enrollments under its license with the state of Florida, Gold Kidney was in violation of 42 C.F.R. §§ 422.504(a)(1) and 423.505(b)(2), which requires MA-PD organizations that contract with CMS to accept new enrollments as provided in 42 C.F.R. Parts 422 and 423, Subpart B.

Effective December 15, 2025, the FL OIR permitted Gold Kidney to accept new enrollments. As a result, Gold Kidney is no longer in violation of CMS regulations and CMS is releasing the intermediate sanction from contract H1526 effective December 15, 2025.

CMS expects Gold Kidney to remain in good standing with the state of Florida. Any future failures to comply with CMS requirements may subject Gold Kidney to other applicable remedies available under law, including the imposition of intermediate sanctions, civil money penalties, or contract termination as described in 42 C.F.R. Parts 422 and 423, Subparts K and O. If you have any questions about this notice, please call or email the enforcement contact provided in your email notification.

Sincerely,

/s/

John A. Scott

Director

Medicare Parts C and D Oversight and Enforcement Group

cc: Kevin Stansbury, CMS/CM/MOEG/DCE
Ashley Hashem, CMS/OPOLE
Scott Labrecque, CMS/OPOLE
Emily Chapple, CMS/OPOLE